Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DA-4505 Monotherapy and Combination with Pembrolizumab in Solid Tumors
NCT06293651Phase 2Recruiting
- Sponsor
- Dong-A ST
- Start
- Apr 2024
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of DA-4505 in solid tumor (2 arms), sponsored by Dong-A ST. Primary endpoints: Proportion of adverse events meeting protocol-defined dose-limiting toxicity criteria, Peak Plasma Concentration at Cycle 2 and 3 more. Started Apr 2024; status: recruiting.
02
Drugs
DA-4505
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06293651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06293651.